Kane Biotech(TSXV) KNE

Market CapCA$5.13M

Since IPO (2003)-98%

5 Year-83%

1 Year-44%

1 Month+0%

CA$0.03

-16.67%

-0.01Today

Kane Biotech last closing stock price
Metric	Price	Date
Last close	CAD 0.03	2026-08-31

Kane Biotech stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-16.67%	CAD 0.03	2026-08-21
1 month	+0%	CAD 0.03	2026-07-31
3 month	-28.57%	CAD 0.04	2026-06-02
Year to date	-37.5%	CAD 0.04	2025-12-31
1 year	-44.44%	CAD 0.05	2025-08-29
3 year	-68.75%	CAD 0.08	2023-09-01
5 year	-83.33%	CAD 0.15	2021-09-01
Since inception	-98.29%	CAD 1.75	2003-05-20

Kane Biotech Financials at a Glance

Market Cap

CA$5.13M

Revenue (TTM)

CA$38.72K

Net Income (TTM)

-CA$2.70M

EPS (TTM)

-CA$0.01

P/E Ratio

-2.05

Dividend

CA$0.00

Beta (Volatility)

0.16 (Low)

Dividend

CA$0.00

Beta (Volatility)

0.16 (Low)

Price

CA$0.03

Volume

7,000

Open

CA$0.03

Price

CA$0.03

Volume

7,000

Open

CA$0.03

Previous Close

CA$0.03

Daily Range

CA$0.03 - CA$0.03

52-Week Range

CA$0.02 - CA$0.05

Estimated Earnings Date

Nov 26, 2026

Dividend

CA$0.00

Beta (Volatility)

0.16 (Low)

Price

CA$0.03

Volume

7,000

Open

CA$0.03

Previous Close

CA$0.03

Daily Range

CA$0.03 - CA$0.03

52-Week Range

CA$0.02 - CA$0.05

Estimated Earnings Date

Nov 26, 2026

KNE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kane Biotech

Kane Biotech Inc. is a biotechnology firm based in Winnipeg, Canada, established in 2001. The company specializes in the research, development, and commercialization of innovative technologies aimed at preventing and removing microbial biofilms.

Products and Services

Pet dental hygiene solutions marketed as StrixNB and bluestem
DispersinB for animal and human wound care
Alosera brand shampoos for dogs, cats, and horses

Growth Outlook

Significant market potential in the pet care and wound care sectors
Continued investment in research and development to enhance product offerings
Strategic partnerships to expand distribution channels globally

Financial Highlights

Recent quarterly revenue of CAD 43,218, showing a focus on growth
Trailing twelve months (TTM) revenue of CAD 1,000,000, indicating market interest
Operating expenses reflect ongoing investment in product development

Headquartered in Winnipeg, Kane Biotech Inc. is positioned in the biotechnology sector, focusing on innovative solutions for both pets and humans. The company's diverse product portfolio includes dental hygiene solutions and wound care products, which are essential in addressing microbial biofilm challenges. With a commitment to research and development, Kane Biotech aims to enhance its offerings and capture a larger market share. The growth outlook is promising, driven by strategic partnerships and a focus on expanding distribution channels. Financially, the company is navigating through a challenging landscape, with recent quarterly revenue reflecting ongoing efforts to establish a foothold in the market. The emphasis on innovation and product development positions Kane Biotech as a noteworthy player in the biotechnology industry.

AI Generated • Aug 2, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Robert B. Huizinga, PhD

Website

www.kanebiotech.com

Headquarters

Winnipeg, MB R3T 6G2, CA

KNE Financials

Key Financial Metrics (TTM)

Gross Margin

-503.12%

Operating Margin

-8113.83%

Net Income Margin

-6980.20%

Return on Equity

273.53%

Return on Capital

-199.79%

Return on Assets

-121.29%

Earnings Yield

-48.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$5.13M

Shares Outstanding

205.06M

Volume

7.00K

Avg. Volume

109.50K

Financials (TTM)

Gross Profit

-CA$194.80K

Operating Income

-CA$3.14M

EBITDA

-CA$3.07M

Operating Cash Flow

-CA$2.50M

Capital Expenditure

CA$76.72K

Free Cash Flow

-CA$2.42M

Cash & ST Invst.

CA$854.73K

Total Debt

CA$1.96M

Kane Biotech Performance Analysis

Kane Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	CAD 156,733	-90.3%
2023	2023-12-31	CAD 148,980	-4.9%
2024	2024-12-31	CAD 2,080,879	1296.8%
2025	2025-12-31	CAD 427,869	-79.4%

Kane Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-69.6%
Q4	2025-12-31	-348.7%
Q1	2026-03-31	304.4%
Q2	2026-06-30	-81.2%

Kane Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	CAD -0.03	-21.3%
2023	2023-12-31	CAD -0.04	23.0%
2024	2024-12-31	CAD -0.02	-42.9%
2025	2025-12-31	CAD -0.02	-25.7%

Kane Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-71.4%
Q4	2025-12-31	16.7%
Q1	2026-03-31	-30.0%
Q2	2026-06-30	-5.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

CA$8.14K

-70.9%

Gross Profit

-CA$11.60K

+74.5%

Gross Margin

-1.42%

N/A

Market Cap

CA$5.13M

N/A

Market Cap/Employee

CA$160.20K

N/A

Employees

N/A

Net Income

-CA$833.64K

-139.2%

EBITDA

-CA$775.44K

-292.7%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

CA$854.73K

-47.0%

Total Debt

CA$1.96M

-24.7%

Accounts Receivable

CA$40.39K

-71.0%

Inventory

CA$480.48K

+43.6%

Long Term Debt

CA$660.33K

-68.0%

Short Term Debt

CA$1.30M

+139.6%

Return on Assets

-1.21%

N/A

Return on Invested Capital

9.42%

N/A

Free Cash Flow

-CA$634.32K

+22.9%

Operating Cash Flow

-CA$634.32K

+17.9%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

APS.TOAptose Biosciences Inc.

APS.TOAptose Biosciences Inc.CA$2.40+0.00%

XRTX.VXORTX Therapeutics Inc.

XRTX.VXORTX Therapeutics Inc.CA$3.19+4.59%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$71.92+0.00%

WETOWetour Robotics

WETOWetour Robotics$5.48-0.04%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$44.67+0.02%

INTCIntel

INTCIntel$89.51+0.00%

NVDANvidia

NVDANvidia$220.78+0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF

TLTiShares Trust - iShares 20+ Year Treasury Bond ETF$82.52-0.00%

Questions About KNE

What is the current price of Kane Biotech?

Kane Biotech is trading at CA$0.03 per share.

What is the 52-week range for Kane Biotech?

Over the past 52 weeks, Kane Biotech has traded between CA$0.02 and CA$0.05.

How much debt does Kane Biotech have?

As of the most recent reporting period, Kane Biotech reported total debt of CA$1.96M.

How much cash does Kane Biotech have on hand?

Kane Biotech reported CA$854.73K in cash and cash equivalents in its most recent financial results.

What is Kane Biotech’s dividend yield?

Kane Biotech does not currently have a dividend yield.

Kane Biotech(TSXV) KNE

Kane Biotech Financials at a Glance

KNE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Kane Biotech

KNE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Kane Biotech Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KNE

What is the current price of Kane Biotech?

What is the 52-week range for Kane Biotech?

How much debt does Kane Biotech have?

How much cash does Kane Biotech have on hand?

What is Kane Biotech’s dividend yield?

Premium Investing Services